All In Biotech

Drug Trial Radar · NCT02198794

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Last checked: Nov 20, 2026Latest source record: Apr 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 343 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

343

Actual

Start

Oct 20, 2014

Primary completion

Dec 6, 2019

Study completion Dec 14, 2020

Sponsor

Lead sponsor
Auspex Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809.

Conditions

  • Tardive Dyskinesia

Interventions

  • SD-809Drug

    SD-809 will be administered per dose and schedule specified in the arm.

  • PlaceboDrug

    Placebo matching to SD-809 will be administered per schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to WithdrawalTime frame: Baseline up to the end of follow-up (4 weeks after the last dose of study drug; mean exposure: up to approximately 866.1 days)
  2. Part B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video RatingTime frame: Day 1 of Part B, Day 7 of Part B

Locations

82 sites in 6 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 145

    Tuscaloosa, Alabama

  • Teva Investigational Site 107

    Anaheim, California

  • Teva Investigational Site 108

    Anaheim, California

  • Teva Investigational Site 123

    Glendale, California

  • Teva Investigational Site 160

    Irvine, California

  • Teva Investigational Site 176

    Loma Linda, California

  • Teva Investigational Site 121

    Los Angeles, California

  • Teva Investigational Site 147

    Los Angeles, California

  • Teva Investigational Site 174

    Norwalk, California

  • Teva Investigational Site 130

    Oceanside, California

  • Teva Investigational Site 102

    Orange, California

  • Teva Investigational Site 104

    San Bernardino, California

  • Teva Investigational Site 110

    San Diego, California

  • Teva Investigational Site 169

    San Rafael, California

  • Teva Investigational Site 129

    Englewood, Colorado

  • Teva Investigational Site 139

    New Haven, Connecticut

  • Teva Investigational Site 156

    Washington D.C., District of Columbia

  • Teva Investigational Site 157

    Boca Raton, Florida

  • Teva Investigational Site 117

    Gainesville, Florida

  • Teva Investigational Site 150

    Lake City, Florida

  • Teva Investigational Site 153

    Miami, Florida

  • Teva Investigational Site 162

    Miami, Florida

  • Teva Investigational Site 112

    Orlando, Florida

  • Teva Investigational Site 144

    Port Charlotte, Florida

  • Teva Investigational Site 155

    Augusta, Georgia

  • Teva Investigational Site 165

    Decatur, Georgia

  • Teva Investigational Site 131

    Chicago, Illinois

  • Teva Investigational Site 154

    Baltimore, Maryland

  • Teva Investigational Site 101

    Glen Burnie, Maryland

  • Teva Investigational Site 118

    Creve Coeur, Missouri

  • Teva Investigational Site 142

    Kansas City, Missouri

  • Teva Investigational Site 175

    St Louis, Missouri

  • Teva Investigational Site 161

    St Louis, Missouri

  • Teva Investigational Site 178

    Lincoln, Nebraska

  • Teva Investigational Site 128

    Albuquerque, New Mexico

  • Teva Investigational Site 146

    Raleigh, North Carolina

  • Teva Investigational Site 114

    Garfield Heights, Ohio

  • Teva Investigational Site 133

    Charleston, South Carolina

  • Teva Investigational Site 149

    Memphis, Tennessee

  • Teva Investigational Site 151

    Fort Worth, Texas

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.